OptimizeRx Corp.

  • Market Cap: Micro Cap
  • Industry: Software Products
  • ISIN: US68401U2042
USD
14.65
0.54 (3.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About OptimizeRx Corp. stock-summary
stock-summary
OptimizeRx Corp.
Software Products
OptimizeRx Corporation is a digital health company that facilitates communication at point-of-care among stakeholders in healthcare. The Company provides electronic clinical information through electronic health records (EHRs) to the medical profession, providing a direct channel for pharmaceutical companies to communicate with healthcare providers. Primarily focused on life science and payer clients, its suite of digital and mobile software as a service (SaaS)-based solutions enables affordability, patient adherence and care management. The Company’s products and applications include financial messaging, brand and clinical messaging, brand support, patient engagement and digital therapeutics. Its integrated financial messaging platform is a virtual patient support center that allows doctors and staff to access a universe of sample vouchers, co-pay coupons and other patient support through their electronic medical record (EMR) and/or e-Prescribe systems.
Company Coordinates stock-summary
Company Details
400 Water St Ste 200 , ROCHESTER MI : 48307-2090
stock-summary
Tel: 1 248 65165581 949 4327557
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 37 Schemes (27.08%)

Foreign Institutions

Held by 38 Foreign Institutions (8.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Gus Halas
Chairman of the Board
Mr. William Febbo
Chief Executive Officer, Director
Mr. Gregory Wasson
Director
Mr. James Lang
Independent Director
Mr. Patrick Spangler
Independent Director
Ms. Lynn Vos
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summary
Industry

Software Products

stock-summary
Market cap

USD 340 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

-1.99%

stock-summary
Price to Book

2.85